IDEAYA Biosciences Inc
IDYA31.990USD
+1.100+3.56%
交易中 （美東）報價延遲15分鐘
2.80B總市值
虧損本益比TTM
關於 IDEAYA Biosciences Inc 公司
IDEAYA Biosciences, Inc. 是一家精準醫療腫瘤學公司。該公司致力於發現和開發針對使用分子診斷選擇的患者羣體的靶向療法。其主要候選產品是 darovasertib (IDE196)、IDE397、IDE161 和 GSK101 (Pol Theta Helicase)。IDE196 是一種小分子蛋白激酶 C (PKC) 抑制劑，與在研 cMET 抑制劑克唑替尼聯合使用。IDE397 是其小分子蛋氨酸腺苷轉移酶 2a (MAT2A) 抑制劑。IDE161 是其小分子聚（ADP-核糖）糖基水解酶 (PARG) 抑制劑。IDE196 是其臨牀階段的 PKC 抑制劑，該公司正在將其評估爲合成致死聯合療法。IDE397 是一種 MAT2A 抑制劑，用於治療具有 MTAP 缺失的實體瘤患者。 IDE161 是其臨牀階段的強效選擇性 PARG 小分子抑制劑，適用於根據基因突變和/或分子特徵具有明確生物標誌物的腫瘤患者。
IDEAYA Biosciences Inc簡介
公司代碼IDYA
公司名稱IDEAYA Biosciences Inc
上市日期May 23, 2019
CEOMr. Yujiro S. Hata
員工數量131
證券類型Ordinary Share
年結日May 23
公司地址7000 Shoreline Ct, Suite 350
城市SOUTH SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94080
電話16504436209
網址https://www.ideayabio.com/
公司代碼IDYA
上市日期May 23, 2019
CEOMr. Yujiro S. Hata
IDEAYA Biosciences Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
Mr. Andres Ruiz Briseno, CPA
Mr. Andres Ruiz Briseno, CPA
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
Chief Accounting Officer, Senior Vice President, Head - Finance and Investor Relations
--
--
Dr. Michael A. White, Ph.D.
Dr. Michael A. White, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Independent Director
Independent Director
--
--
Mr. Yujiro S. Hata
Mr. Yujiro S. Hata
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Joshua Bleharski, Ph.D.
Dr. Joshua Bleharski, Ph.D.
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Catherine J. Mackey, Ph.D.
Dr. Catherine J. Mackey, Ph.D.
Independent Director
Independent Director
--
--
Dr. M. Garret Hampton, Ph.D.
Dr. M. Garret Hampton, Ph.D.
Independent Director
Independent Director
--
--
Dr. Terry J. Rosen, Ph.D.
Dr. Terry J. Rosen, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Darrin Beaupre, M.D., Ph.D.
Dr. Darrin Beaupre, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Dr. Jeffrey L. (Jeff) Stein, Ph.D.
Independent Director
Independent Director
--
--
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2024
FY2024Q4
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
業務USD
名稱
營收
佔比
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
地區USD
名稱
營收
佔比
United States
7.00M
100.00%
業務
地區
業務USD
名稱
營收
佔比
WRN
7.00M
0.00%
MAT2A
0.00
0.00%
Pol Theta
0.00
0.00%
股東統計
更新時間: 9月29日 週一
更新時間: 9月29日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
7.61%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.08%
Capital World Investors
6.70%
其他
56.15%
持股股東
持股股東
佔比
Fidelity Management & Research Company LLC
14.99%
BlackRock Institutional Trust Company, N.A.
7.61%
Capital Research Global Investors
7.47%
Janus Henderson Investors
7.08%
Capital World Investors
6.70%
其他
56.15%
股東類型
持股股東
佔比
Investment Advisor
55.67%
Investment Advisor/Hedge Fund
32.03%
Hedge Fund
20.82%
Venture Capital
6.27%
Research Firm
3.91%
Individual Investor
0.90%
Pension Fund
0.90%
Bank and Trust
0.38%
Private Equity
0.16%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
460
105.73M
120.62%
-11.57M
2025Q2
449
101.70M
116.06%
-6.32M
2025Q1
454
97.81M
111.68%
-11.15M
2024Q4
442
95.26M
108.96%
-7.87M
2024Q3
426
95.20M
112.79%
+2.56M
2024Q2
409
85.26M
112.59%
-3.91M
2024Q1
388
81.45M
108.91%
-1.44M
2023Q4
351
68.31M
105.94%
-512.62K
2023Q3
331
61.92M
105.66%
-3.64M
2023Q2
313
59.35M
103.37%
+5.88M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Fidelity Management & Research Company LLC
13.14M
14.99%
+7.07K
+0.05%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
6.67M
7.61%
-480.56K
-6.72%
Jun 30, 2025
Capital Research Global Investors
6.55M
7.48%
+3.82M
+139.59%
Jun 30, 2025
Janus Henderson Investors
6.21M
7.08%
-195.54K
-3.05%
Jun 30, 2025
Capital World Investors
5.87M
6.7%
+3.38M
+136.15%
Jun 30, 2025
Point72 Asset Management, L.P.
5.03M
5.74%
+4.89M
+3488.42%
Jun 30, 2025
The Vanguard Group, Inc.
4.92M
5.62%
-152.94K
-3.01%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
4.63M
5.28%
-140.66K
-2.95%
Jun 30, 2025
Deerfield Management Company, L.P.
3.92M
4.47%
+647.76K
+19.82%
Jun 30, 2025
State Street Investment Management (US)
3.39M
3.86%
-60.44K
-1.75%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月6日 週四
更新時間: 11月6日 週四
機構名稱
佔比
Tema Oncology ETF
2.53%
ALPS Medical Breakthroughs ETF
1.42%
Virtus LifeSci Biotech Clinical Trials ETF
0.88%
Invesco Dorsey Wright Healthcare Momentum ETF
0.76%
SPDR S&P Biotech ETF
0.65%
Direxion Daily S&P Biotech Bull 3X Shares
0.34%
ProShares Ultra Nasdaq Biotechnology
0.25%
Avantis US Small Cap Equity ETF
0.25%
Invesco Nasdaq Biotechnology ETF
0.24%
iShares Biotechnology ETF
0.21%
查看更多
Tema Oncology ETF
佔比2.53%
ALPS Medical Breakthroughs ETF
佔比1.42%
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.88%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比0.76%
SPDR S&P Biotech ETF
佔比0.65%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.34%
ProShares Ultra Nasdaq Biotechnology
佔比0.25%
Avantis US Small Cap Equity ETF
佔比0.25%
Invesco Nasdaq Biotechnology ETF
佔比0.24%
iShares Biotechnology ETF
佔比0.21%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
